Integrated Filing- Financial

Anlon Healthcare Limited has announced a board meeting to consider the financial results for the quarter and half-year ending June 30, 2026. The company is also pursuing an acquisition of 32.52% in Apiqo Organics Private Limited and 43.33% in Bizotic LifeScience Private Limited, aiming to make them wholly-owned subsidiaries through a share swap arrangement. **1. Financial Performance (Consolidated):** - Revenue from Operations: Rs. 8,756.27 Cr - Total Income: Rs. 8,762.23 Cr - Year-on-Year growth in revenue is substantial, driven by increased operational scale. **2. Profitability and EPS:** - Profit after tax: Rs. 828.14 Cr - Basic EPS: Rs. 0.16 - Profitability saw a dip compared to the previous quarter, primarily due to a significant increase in the cost of materials consumed. **3. Growth Drivers & Expense Trends:** - Revenue growth in the consolidated segment appears robust. - Key expenses like "Cost of materials consumed" and "Depreciation and amortization expense" have increased substantially in the consolidated segment compared to the previous quarter. **4. Final Lens for Investors:** The results show strong revenue growth but a notable contraction in profitability this quarter, warranting a closer look at cost management.